5 news items
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
BLRX
17 May 24
on BioLineRx's business; and the impact of the COVID-19 pandemic, the Russian invasion
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
BLRX
6 May 24
on BioLineRx's business; the impact of any resurgence of the COVID-19 pandemic, the Russian invasion
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
BLRX
17 Apr 24
in Israel on BioLineRx's business; the impact of any resurgence of the COVID-19 pandemic, the Russian
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
BLRX
4 Mar 24
in Israel on BioLineRx's business; and the impact of the COVID-19 pandemic, the Russian
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
BLRX
28 Feb 24
in Israel on BioLineRx's business; and the impact of the COVID-19 pandemic, the Russian invasion
- Prev
- 1
- Next